CN103356807A - 一种具有增强免疫力功能的组合物及其制备方法 - Google Patents
一种具有增强免疫力功能的组合物及其制备方法 Download PDFInfo
- Publication number
- CN103356807A CN103356807A CN2012100914136A CN201210091413A CN103356807A CN 103356807 A CN103356807 A CN 103356807A CN 2012100914136 A CN2012100914136 A CN 2012100914136A CN 201210091413 A CN201210091413 A CN 201210091413A CN 103356807 A CN103356807 A CN 103356807A
- Authority
- CN
- China
- Prior art keywords
- radix
- preparation
- poria
- fructus lycii
- add
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 35
- 239000003814 drug Substances 0.000 title claims abstract description 34
- 230000002708 enhancing effect Effects 0.000 title claims abstract description 14
- 230000036039 immunity Effects 0.000 title claims abstract description 14
- 229940079593 drug Drugs 0.000 title abstract description 8
- 239000002131 composite material Substances 0.000 title abstract 5
- 239000009636 Huang Qi Substances 0.000 claims abstract description 34
- 239000000203 mixture Substances 0.000 claims abstract description 22
- 238000009472 formulation Methods 0.000 claims abstract description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 41
- 241001619461 Poria <basidiomycete fungus> Species 0.000 claims description 32
- 238000001035 drying Methods 0.000 claims description 25
- 239000000843 powder Substances 0.000 claims description 19
- 239000008187 granular material Substances 0.000 claims description 18
- 230000000694 effects Effects 0.000 claims description 14
- 238000002481 ethanol extraction Methods 0.000 claims description 12
- 239000007788 liquid Substances 0.000 claims description 11
- 238000000034 method Methods 0.000 claims description 11
- 238000002156 mixing Methods 0.000 claims description 10
- 230000006837 decompression Effects 0.000 claims description 9
- 239000000284 extract Substances 0.000 claims description 9
- 238000004064 recycling Methods 0.000 claims description 9
- 239000000463 material Substances 0.000 claims description 7
- 239000002671 adjuvant Substances 0.000 claims description 5
- 238000005469 granulation Methods 0.000 claims description 5
- 230000003179 granulation Effects 0.000 claims description 5
- 239000003826 tablet Substances 0.000 claims description 5
- 239000002775 capsule Substances 0.000 claims description 4
- 239000006187 pill Substances 0.000 claims description 4
- 239000000706 filtrate Substances 0.000 claims description 3
- 239000012467 final product Substances 0.000 claims description 2
- 235000013402 health food Nutrition 0.000 claims description 2
- 241000208340 Araliaceae Species 0.000 abstract description 4
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 abstract description 3
- 235000003140 Panax quinquefolius Nutrition 0.000 abstract description 3
- 235000008434 ginseng Nutrition 0.000 abstract description 3
- 235000017784 Mespilus germanica Nutrition 0.000 abstract description 2
- 235000000560 Mimusops elengi Nutrition 0.000 abstract description 2
- 244000197580 Poria cocos Species 0.000 abstract description 2
- 235000008599 Poria cocos Nutrition 0.000 abstract description 2
- 235000007837 Vangueria infausta Nutrition 0.000 abstract description 2
- 241001632410 Eleutherococcus senticosus Species 0.000 abstract 1
- 240000002624 Mespilus germanica Species 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 12
- -1 syringaresinol glycosides Chemical class 0.000 description 10
- 230000006870 function Effects 0.000 description 9
- 238000005303 weighing Methods 0.000 description 9
- 239000002994 raw material Substances 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 238000000605 extraction Methods 0.000 description 7
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 238000001914 filtration Methods 0.000 description 5
- 210000002216 heart Anatomy 0.000 description 5
- 210000004185 liver Anatomy 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 238000005728 strengthening Methods 0.000 description 5
- 208000004880 Polyuria Diseases 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 230000035619 diuresis Effects 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 230000001717 pathogenic effect Effects 0.000 description 4
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- 206010061598 Immunodeficiency Diseases 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 235000001014 amino acid Nutrition 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 230000001093 anti-cancer Effects 0.000 description 3
- 230000002421 anti-septic effect Effects 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 230000036772 blood pressure Effects 0.000 description 3
- 210000000988 bone and bone Anatomy 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000029087 digestion Effects 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 239000007789 gas Substances 0.000 description 3
- 150000004676 glycans Chemical class 0.000 description 3
- 230000036737 immune function Effects 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 3
- 239000008108 microcrystalline cellulose Substances 0.000 description 3
- 229940016286 microcrystalline cellulose Drugs 0.000 description 3
- 210000003205 muscle Anatomy 0.000 description 3
- 239000002674 ointment Substances 0.000 description 3
- 229940023488 pill Drugs 0.000 description 3
- 229920001282 polysaccharide Polymers 0.000 description 3
- 239000005017 polysaccharide Substances 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 210000000952 spleen Anatomy 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- 239000004094 surface-active agent Substances 0.000 description 3
- YDZWHGJRWMQCDP-NKILCQAGSA-N (2s,3s,4s,5r,6r)-6-[[(3s,4ar,6ar,6bs,8as,12as,14ar,14br)-8a-carboxy-4,4,6a,6b,11,11,14b-heptamethyl-1,2,3,4a,5,6,7,8,9,10,12,12a,14,14a-tetradecahydropicen-3-yl]oxy]-3-hydroxy-4-[(2s,3r,4s,5r,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-5-[(2s,3r,4 Chemical compound O([C@H]1[C@H](O)[C@H](O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@H]1CC[C@]2(C)[C@H]3CC=C4[C@@]([C@@]3(CC[C@H]2C1(C)C)C)(C)CC[C@]1(CCC(C[C@H]14)(C)C)C(O)=O)C(O)=O)[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O YDZWHGJRWMQCDP-NKILCQAGSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- 108010011485 Aspartame Proteins 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- 239000004375 Dextrin Substances 0.000 description 2
- 229920001353 Dextrin Polymers 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- 241000201295 Euphrasia Species 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 229920000881 Modified starch Polymers 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 239000000605 aspartame Substances 0.000 description 2
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 2
- 229960003438 aspartame Drugs 0.000 description 2
- 235000010357 aspartame Nutrition 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 230000001914 calming effect Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 235000008504 concentrate Nutrition 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 239000000287 crude extract Substances 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 235000019425 dextrin Nutrition 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 239000007938 effervescent tablet Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 229930182470 glycoside Natural products 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 201000002364 leukopenia Diseases 0.000 description 2
- 231100001022 leukopenia Toxicity 0.000 description 2
- 229940040145 liniment Drugs 0.000 description 2
- 239000000865 liniment Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 210000000214 mouth Anatomy 0.000 description 2
- 229940126701 oral medication Drugs 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 230000035790 physiological processes and functions Effects 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 235000013619 trace mineral Nutrition 0.000 description 2
- 239000011573 trace mineral Substances 0.000 description 2
- FTLYMKDSHNWQKD-UHFFFAOYSA-N (2,4,5-trichlorophenyl)boronic acid Chemical compound OB(O)C1=CC(Cl)=C(Cl)C=C1Cl FTLYMKDSHNWQKD-UHFFFAOYSA-N 0.000 description 1
- OILXMJHPFNGGTO-UHFFFAOYSA-N (22E)-(24xi)-24-methylcholesta-5,22-dien-3beta-ol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(C)C(C)C)C1(C)CC2 OILXMJHPFNGGTO-UHFFFAOYSA-N 0.000 description 1
- RQOCXCFLRBRBCS-UHFFFAOYSA-N (22E)-cholesta-5,7,22-trien-3beta-ol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CCC(C)C)CCC33)C)C3=CC=C21 RQOCXCFLRBRBCS-UHFFFAOYSA-N 0.000 description 1
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- AXTGDCSMTYGJND-UHFFFAOYSA-N 1-dodecylazepan-2-one Chemical compound CCCCCCCCCCCCN1CCCCCC1=O AXTGDCSMTYGJND-UHFFFAOYSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 1
- OQMZNAMGEHIHNN-UHFFFAOYSA-N 7-Dehydrostigmasterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CC(CC)C(C)C)CCC33)C)C3=CC=C21 OQMZNAMGEHIHNN-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- DHHFDKNIEVKVKS-FMOSSLLZSA-N Betanin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC(C(=C1)O)=CC(C[C@H]2C([O-])=O)=C1[N+]2=C\C=C\1C=C(C(O)=O)N[C@H](C(O)=O)C/1 DHHFDKNIEVKVKS-FMOSSLLZSA-N 0.000 description 1
- DHHFDKNIEVKVKS-MVUYWVKGSA-N Betanin Natural products O=C(O)[C@@H]1NC(C(=O)O)=C/C(=C\C=[N+]/2\[C@@H](C(=O)[O-])Cc3c\2cc(O)c(O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)c3)/C1 DHHFDKNIEVKVKS-MVUYWVKGSA-N 0.000 description 1
- 239000004255 Butylated hydroxyanisole Substances 0.000 description 1
- 239000004322 Butylated hydroxytoluene Substances 0.000 description 1
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 1
- 241000282461 Canis lupus Species 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 206010010144 Completed suicide Diseases 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- DNVPQKQSNYMLRS-NXVQYWJNSA-N Ergosterol Natural products CC(C)[C@@H](C)C=C[C@H](C)[C@H]1CC[C@H]2C3=CC=C4C[C@@H](O)CC[C@]4(C)[C@@H]3CC[C@]12C DNVPQKQSNYMLRS-NXVQYWJNSA-N 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 206010016326 Feeling cold Diseases 0.000 description 1
- 208000012895 Gastric disease Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000004378 Glycyrrhizin Substances 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 206010024419 Libido decreased Diseases 0.000 description 1
- 229920000161 Locust bean gum Polymers 0.000 description 1
- 244000241838 Lycium barbarum Species 0.000 description 1
- 235000015459 Lycium barbarum Nutrition 0.000 description 1
- 244000182216 Mimusops elengi Species 0.000 description 1
- 239000004368 Modified starch Substances 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 229920003081 Povidone K 30 Polymers 0.000 description 1
- 241000576755 Sclerotia Species 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 239000004141 Sodium laurylsulphate Substances 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 241000208292 Solanaceae Species 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- UEDUENGHJMELGK-HYDKPPNVSA-N Stevioside Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UEDUENGHJMELGK-HYDKPPNVSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000001785 acacia senegal l. willd gum Substances 0.000 description 1
- 230000004308 accommodation Effects 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 229940023476 agar Drugs 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- 231100000360 alopecia Toxicity 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000002605 anti-dotal effect Effects 0.000 description 1
- 230000003471 anti-radiation Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 239000001654 beetroot red Substances 0.000 description 1
- 235000012677 beetroot red Nutrition 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 235000002185 betanin Nutrition 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 229940046011 buccal tablet Drugs 0.000 description 1
- 239000006189 buccal tablet Substances 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- 235000011132 calcium sulphate Nutrition 0.000 description 1
- 229960001631 carbomer Drugs 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000007910 chewable tablet Substances 0.000 description 1
- 229940068682 chewable tablet Drugs 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229960004106 citric acid Drugs 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 238000000151 deposition Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- 239000007919 dispersible tablet Substances 0.000 description 1
- 238000011978 dissolution method Methods 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 206010013990 dysuria Diseases 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 235000018927 edible plant Nutrition 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- DNVPQKQSNYMLRS-SOWFXMKYSA-N ergosterol Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H](CC[C@]3([C@H]([C@H](C)/C=C/[C@@H](C)C(C)C)CC[C@H]33)C)C3=CC=C21 DNVPQKQSNYMLRS-SOWFXMKYSA-N 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 229960001617 ethyl hydroxybenzoate Drugs 0.000 description 1
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 229940014259 gelatin Drugs 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 230000003284 homeostatic effect Effects 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 230000036543 hypotension Effects 0.000 description 1
- 230000037451 immune surveillance Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 208000033065 inborn errors of immunity Diseases 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 210000004153 islets of langerhan Anatomy 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- ZOLPMMWNCLHKPX-UHFFFAOYSA-N ligustrin Natural products CC1=CCC2C1C3OC(=C)C(=O)C3C(O)CC2=C ZOLPMMWNCLHKPX-UHFFFAOYSA-N 0.000 description 1
- 235000010420 locust bean gum Nutrition 0.000 description 1
- 239000000711 locust bean gum Substances 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 235000014380 magnesium carbonate Nutrition 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 229960001855 mannitol Drugs 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 235000019426 modified starch Nutrition 0.000 description 1
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- GYCKQBWUSACYIF-UHFFFAOYSA-N o-hydroxybenzoic acid ethyl ester Natural products CCOC(=O)C1=CC=CC=C1O GYCKQBWUSACYIF-UHFFFAOYSA-N 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 229920001495 poly(sodium acrylate) polymer Polymers 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 229940068984 polyvinyl alcohol Drugs 0.000 description 1
- 239000001253 polyvinylpolypyrrolidone Substances 0.000 description 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 239000004302 potassium sorbate Substances 0.000 description 1
- 229940069338 potassium sorbate Drugs 0.000 description 1
- 235000010241 potassium sorbate Nutrition 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 208000028529 primary immunodeficiency disease Diseases 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000004223 radioprotective effect Effects 0.000 description 1
- 230000003014 reinforcing effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229940085605 saccharin sodium Drugs 0.000 description 1
- 238000007560 sedimentation technique Methods 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 229940001593 sodium carbonate Drugs 0.000 description 1
- 235000017550 sodium carbonate Nutrition 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- NNMHYFLPFNGQFZ-UHFFFAOYSA-M sodium polyacrylate Chemical compound [Na+].[O-]C(=O)C=C NNMHYFLPFNGQFZ-UHFFFAOYSA-M 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000001256 steam distillation Methods 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 229940013618 stevioside Drugs 0.000 description 1
- OHHNJQXIOPOJSC-UHFFFAOYSA-N stevioside Natural products CC1(CCCC2(C)C3(C)CCC4(CC3(CCC12C)CC4=C)OC5OC(CO)C(O)C(O)C5OC6OC(CO)C(O)C(O)C6O)C(=O)OC7OC(CO)C(O)C(O)C7O OHHNJQXIOPOJSC-UHFFFAOYSA-N 0.000 description 1
- 235000019202 steviosides Nutrition 0.000 description 1
- 208000018556 stomach disease Diseases 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 238000000194 supercritical-fluid extraction Methods 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- LVUPFEOCDSHRBL-UHFFFAOYSA-N syringaresinol Natural products COc1cccc(OC)c1C2OCC3C2COC3c4c(OC)cccc4OC LVUPFEOCDSHRBL-UHFFFAOYSA-N 0.000 description 1
- QJVXKWHHAMZTBY-GCPOEHJPSA-N syringin Chemical compound COC1=CC(\C=C\CO)=CC(OC)=C1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 QJVXKWHHAMZTBY-GCPOEHJPSA-N 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 229940033663 thimerosal Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
本发明公开了一种具有增强免疫力功能的药物组合物及其制备方法。该组合物是由西洋参、枸杞子、刺五加、茯苓、炙黄芪按一定重量配比制备而成,它可以被制成任何一种常用制剂,优选口服制剂。本发明药物组合物具有增强机体免疫力的功能。
Description
技术领域
本发明涉及一种具有增强免疫力功能的组合物及其制备方法,属于保健食品的技术领域。
背景技术
免疫系统是覆盖全身的防卫网络,保护身体的第一道防线。免疫系统(immunologicfunction)是生物机体在种系进化和个体发育过程中逐步获得的防卫能力。主要包括三个方面:机体抵抗外界传染性因子的免疫防护功能;机体清除损伤和死亡细胞,维持自身生理平衡的自身稳定功能;对机体监视,发现并清除突变细胞的免疫监视功能。在正常生理条件下,机体的免疫系统依靠其先天具有的免疫能力及后天获得的免疫能力发挥共同免疫作用,保持机体的生理功能相对稳定。若免疫功能发生异常,必然会导致机体生理功能的失调,从而出现病理性变化。而中医理论认为一切致病因素为邪气,一切抗病能力为正气。正气,又分为卫气、元气和主要组织器官的脏腑之气等。所谓卫气是能起防御外邪侵犯人体的正气。如果正气旺盛,机体就能祛邪外出,免于生病,即所谓“正气内存,邪不可干”。如果正气虚衰,则邪气容易侵入机体而引起疾病,即所谓致病是由于“邪之所揍,其气必虚”。因此中医在防病治病过程中提出的扶正祛邪以固本的基本原则,与增强机体免疫力的保健方法是一致的。
发明内容
本发明目的是提供了一种具有增强免疫力的组合物。
本发明的另外一个目的是提供了该组合物的制备方法。
本发明是通过以下技术方案实现的:
本发明是由下述重量份的原料制成的:
西洋参1-25份、枸杞子1-20份、刺五加1-15份、茯苓1-20份、炙黄芪1-20份。
优选为:
西洋参5-15份、枸杞子3-10份、刺五加3-8份、茯苓3-10份、炙黄芪3-10份。
更优选为:
西洋参8-10份、枸杞子5-8份、刺五加4-6份、茯苓5-8份、炙黄芪5-8份。
本发明中各组分的作用机理如下:
西洋参:是药食同源植物,既是名贵上品中药,又是高级滋补佳品。具有滋阴补气,宁神益智及清热生津,降火消暑的双重功效。古语云:“西洋参性凉而补,凡欲用人参而不受人参之温者皆可用之”。故补而不燥是西洋参的特别之处。它含有人体必需的16种微量元素和17种以上氨基酸和多糖、多肽及多种维生素等,具有抗癌、抗疲劳、抗缺氧、抗辐射、抗衰老等多种功能。其主要作用有:强化心肌及增强心脏之活动能力;强壮中枢神经,安定身心并恢复疲劳,有镇静及解酒作用,增强记忆能力,对老人痴呆症有显著功效;对血压有调整作用,使暂时性或持久性血压下降;抑制动脉硬化并促进红血球生长,增加血色素的份量;能调节胰岛之分泌,因此对糖尿病有功效;对肝脏有调节副肾上腺素之分泌,促进新陈代谢的作用;能增强体力并对运动员具极大助益;抑制癌细胞生长,增加免疫功能;助长消化,对慢性胃病和肠胃衰弱有助效。
枸杞子:为茄科植物枸杞之成熟果实,它在祖国的传统医学中具有重要的地位,其药用价值备受历代医家的推崇。《本草纲目》中记载:“枸杞,补肾生精,养肝,明目,坚筋骨,去疲劳,易颜色,变白,明目安神,令人长寿。”长期食用枸杞,有治疗体质虚寒、性冷淡、便秘、失眠、低血压、贫血、掉发以及护肤等作用。中医很早就有“枸杞养生”的说法,认为它能够滋补肝肾、益精明目、养血,增强人们的免疫力,常吃枸杞能“坚筋骨、轻身不老、耐寒暑”。现代研究也表明,它具有增强免疫力、延缓衰老、抗癌等作用,所以,它常常被当作滋补调养和抗衰老的良药。
刺五加:为五加科植物刺五加和五梗五加的根皮,见于《神农本草经》,列为上品。味辛、微苦、性微温。归脾、肾、心经。具有祛风湿;补肝肾;强筋骨;活血脉的功效。刺五加多糖(PES.)及其甙B(紫丁香甙)、D和E(两种构型的紫丁香树脂酚甙)均能明显提高细胞产生诱生干扰素的能力,对S801和S7811白血病细胞系的促诱生能力以PES(纯品)最佳,PES及其甙B、D、E次之。Op刺五加(50g/kg)对皮下注射环磷酰胺引起的白血球减少症有保护作用,对苯引起的小鼠和兔的白血球减少症亦有显著的预防作用。
茯苓:为多孔菌科真菌茯苓Poria cocos(Schw.)Wolf的干燥菌核。性味甘淡平,入心、肺、脾经。具有渗湿利水,健脾和胃,宁心安神的功效。可治小便不利,水肿胀满,痰饮咳逆,呕逆,恶阻,泄泻,遗精,淋浊,惊悸,健忘等症。含茯苓多糖、葡萄糖、蛋白质、氨基酸、有机酸、脂肪、卵磷脂、腺嘌呤、胆碱、麦角甾醇、多种酶和钾盐。能增强机体免疫功能,茯苓多糖有明显的抗肿瘤作用;有利尿作用,能增加尿中钾、钠、氯等电解质的排出;有镇静及保护肝脏、抑制溃疡的发生、降血糖、抗放射等作用。
黄芪:传统中医学认为,黄芪具有补气升阳、固表止汗、托毒排脓、利水消肿、敛疮生肌的功效。现代药理研究表明,黄芪中含有多糖、蛋白质、生物碱、氨基酸、黄酮类、甙类、微量元素等多种生物活性物质,具有增强机体免疫功能,强心降压、降血糖、利尿、抗衰老、抗疲劳、抗肿瘤、抗病毒、镇静、镇痛等作用。
本发明药物可以采用中药制剂的常规方法制备成任何常规的制剂,包括口服制剂,外用制剂,注射剂。例如可以将这些原料药研成粉末混合均匀;可以将所述重量份的原料药分别加水或不同浓度的乙醇提取,提取液浓缩干燥得粗提物,或采用精制方法,例如,水提醇沉法、有机溶剂萃取法、柱层析法、二氧化碳超临界萃取法、水蒸气蒸馏法进行精制得到精提物。
在使用上述药物时,既可以采用以相当于所述重量配比的药物为原料分别净选,干燥、粉碎、混合得到符合制剂要求粒度的颗粒或粉末直接服用。也可以采用以相当于所述重量配比关系的药物为原料经过适当处理后添加药用辅料,根据需要将其制成各种制剂。由上述原料药制备成制剂的过程中,上述原料药可以采用如下方法进行处理:分别加水或不同浓度的乙醇提取,提取液浓缩干燥得粗提物;或进一步采用醇沉法、水返溶法、有机溶剂萃取法、絮凝沉淀法、柱层析法的一种或几种联合使用进行适当精制后得精提物;在对上述有效药用成分进行提取时可采用的具体操作和/或使用方法,既可以是以所述的各比例量的药物成分为原料,分别提取其有效药用成分后再混合的方式,也可以采用按所说比例量的各药物原料混合后再共同提取的方式。采用不同的提取手段、设备及提取时所需的理想或最佳的提取温度、溶剂用量、提取时间、提取次数等具体条件,则可根据实际情况通过试验被筛选和找到。
为了使该药物的各原料更好的发挥药效,优选对本发明所述配比的原料进行醇提取,但不能用于限制本发明的保护范围。
本发明组合物的制备方法如下:
将所述配比的西洋参、枸杞子、刺五加、茯苓、炙黄芪,加乙醇进行提取,提取液合并,过滤,滤液浓缩至稠膏,减压干燥,粉碎成细粉,即得本发明药物的活性成分。
本发明组合物的制备方法优选为:
将所述重量配比的西洋参、枸杞子、刺五加、茯苓、炙黄芪,加6-12倍量50-95%乙醇提取1-4次,每次1-3小时,提取液合并,过滤,减压回收乙醇至稠膏,减压干燥,粉碎成细粉,即得本发明药物的活性成分。
本发明组合物的制备方法还可以为:
将所述重量配比的西洋参、枸杞子、刺五加、茯苓、炙黄芪,加6-12倍量水提取1-4次,每次1-3小时,提取液合并,过滤,滤液浓缩至稠膏,干燥,粉碎成细粉,即得本发明药物的活性成分。
制得的本发明药物活性成分可以直接入药服用或加入药剂学上可接受的辅料按常规工艺制备成所需制剂。如可以制成常用的片剂(分散片、泡腾片、口腔崩解片、含片、咀嚼片、泡腾片)、胶囊剂(硬胶囊、软胶囊剂)、颗粒剂、丸剂(滴丸剂)、散剂等固体制剂形式的口服药物,也可以制成糖浆、口服液等液体制剂形式的口服药物;还可以制成膏剂、凝胶剂、软膏剂、巴布剂、贴膏剂、搽剂、洗剂、涂膜剂等外用制剂形式的外用药物。因此,该药物组合物中除有效成分外,还可以含有药学上可以接受的辅料。
这里所述的辅料,可以根据不同的制剂有所不同,如在片剂、胶囊剂、颗粒剂等固体制剂中常用的稀释剂、崩解剂、赋形剂、粘合剂、润滑剂、表面活性剂、填充剂等;在糖浆、口服液等液体制剂形式中常用的表面活性剂、稀释剂、防腐剂、稳定剂、矫味剂、增稠剂、助流剂等;在凝胶剂、软膏剂等外用制剂形式中常用的药用油性基质、水性基质、防腐剂、抗氧剂、保湿剂、透皮吸收促进剂、表面活性剂等。
其常用辅料如淀粉、乳糖、糊精、糖粉、微晶纤维素、甘露醇、木糖醇、聚乙二醇、硫酸钙、磷酸氢钙、碳酸钙、改良淀粉、山梨醇、聚乙烯吡咯酮、重质碳酸镁、羧甲基纤维素钠、羟丙甲基纤维素、甲基纤维素、乙基纤维素、羧甲淀粉钠、羟丙基纤维素、聚维酮K30、白陶土、预胶化淀粉、硬脂酸镁、滑石粉、微粉硅胶、甜叶菊苷、甜菜碱、阿司帕坦、甘草甜素、糖精钠、枸橼酸、碳酸氢钠、碳酸钠、卡拉胶、琼脂、明胶、海藻酸钠、黄原胶、瓜耳豆胶、西黄耆胶、阿拉伯胶、槐豆胶、刺梧桐胶、硬脂酸、单硬脂酸甘油酯、聚丙烯酰胺、交联型聚丙烯酸钠、聚乙烯醇、卡波姆、山梨酸、山梨酸钾、羟苯乙酯、苯甲醇、尼泊金、硫柳汞、二甲基亚砜、氮酮、三乙醇胺、氢氧化钠、甘油、丙二醇、BHT、BHA、十二烷基硫酸钠、吐温类、司盘类等。
对于上面提到的制剂,本发明优选颗粒剂,制备方法如下:
将所述重量配比的西洋参、枸杞子、刺五加、茯苓、炙黄芪,加8倍量70%乙醇提取3次,每次1.5小时,提取液合并,过滤,减压回收乙醇至稠膏,减压干燥,粉碎成细粉,加入适量辅料,混匀,以85%乙醇制粒,干燥,整粒,即得。
本发明涉及一种用于增强机体免疫力的组合物,是一种纯天然的无毒副作用的营养物质,区别于由化学成分制作的同类产品。
具体实施方式
实施例1:
西洋参90g、枸杞子60g、刺五加50g、茯苓60g、炙黄芪70g。
称取所述重量配比的西洋参、枸杞子、刺五加、茯苓、炙黄芪,加8倍量70%乙醇提取3次,每次1.5小时,提取液合并,过滤,减压回收乙醇至稠膏,减压干燥,粉碎成细粉,加入蔗糖、阿司帕坦,糊精适量,混匀,以85%乙醇制粒,干燥,整粒,即得颗粒剂。
实施例2:
西洋参10g、枸杞子200g、刺五加10g、茯苓200g、炙黄芪10g
称取所述重量配比的西洋参、枸杞子、刺五加、茯苓、炙黄芪,加12倍量50%乙醇提取2次,每次2小时,提取液合并,过滤,减压回收乙醇至稠膏,减压干燥,粉碎成细粉,加入乳糖、甘露醇适量,混匀,以85%乙醇制粒,干燥,整粒,即得颗粒剂。
实施例3:
西洋参250g、枸杞子10g、刺五加150g、茯苓10g、炙黄芪200g
称取所述重量配比的西洋参、枸杞子、刺五加、茯苓、炙黄芪,加6倍量95%乙醇提取4次,每次1小时,提取液合并,过滤,减压回收乙醇至稠膏,减压干燥,粉碎成细粉,加入微晶纤维素、乳糖适量,混匀,制粒,干燥,整粒,即得颗粒剂。
实施例4:
西洋参50g、枸杞子100g、刺五加30g、茯苓100g、炙黄芪30g
称取所述重量配比的西洋参、枸杞子、刺五加、茯苓、炙黄芪,加10倍量80%乙醇提取3次,每次1小时,提取液合并,过滤,减压回收乙醇至稠膏,减压干燥,粉碎成细粉,羧甲基淀粉钠、微粉硅胶、微晶纤维素、交联聚维酮适量,混匀,制粒,干燥,加入硬脂酸镁,混匀,压片,包衣或不包衣,即得片剂。
实施例5:
西洋参150g、枸杞子30g、刺五加80g、茯苓30g、炙黄芪100g
称取所述重量配比的西洋参、枸杞子、刺五加、茯苓、炙黄芪,加7倍量60%乙醇提取1次,每次3小时,提取液过滤,减压回收乙醇至稠膏,减压干燥,粉碎成细粉,加入适量辅料,混匀,制粒,干燥,装胶囊,即得胶囊剂。
实施例6:
西洋参120g、枸杞子100g、刺五加80g、茯苓90g、炙黄芪50g
称取所述重量配比的西洋参、枸杞子、刺五加、茯苓、炙黄芪,加8倍量水提取3次,每次2小时,提取液过滤,浓缩至稠膏,减压干燥,粉碎成细粉,加入辅料适量,混匀,制成丸剂。
实施例7:
西洋参20g、枸杞子150g、刺五加100g、茯苓120g、炙黄芪80g
称取所述重量配比的西洋参、枸杞子、刺五加、茯苓、炙黄芪,加8倍量60%乙醇提取3次,每次2小时,提取液过滤,回收乙醇至无醇味,适当浓缩,加入适量的混悬剂、调味剂、防腐剂,混匀,加水定容,滤过,分装,即得口服液体制剂。
实施例8:
西洋参70g、枸杞子110g、刺五加110g、茯苓90g、炙黄芪100g
称取所述重量配比的西洋参、枸杞子、刺五加、茯苓、炙黄芪,加12倍量水提取2次,每次3小时,提取液过滤,浓缩至稠膏,减压干燥,粉碎成细粉,制成散剂。
实施例9:
西洋参30g、枸杞子40g、刺五加80g、茯苓90g、炙黄芪90g
称取所述重量配比的西洋参、枸杞子、刺五加、茯苓、炙黄芪,加10倍量水提取1次,每次3小时,提取液过滤,浓缩至稠膏,减压干燥,粉碎成细粉,加入适量辅料,制粒,干燥,整粒,即得颗粒剂。
通过以下实验进一步阐述本发明所述组合物的有益效果:
1、临床资料:选取100例免疫力低下患者为治疗对象,其中男性48人,女性52人,年龄为20-60岁,平均38.8岁。
2、疗效评定标准
显效:体质明显增强,四肢有力,精力充沛,脸色改善,睡眠和消化等方面亚健康状态明显改善;
有效:体质有所增强,四肢较有利,精力和脸色均有所好转,睡眠和消化等方面的亚健康状态有所改善;
无效:症状及各项检查未见改善。
3、治疗方法:口服本发明药物(由实施例1制备得到),每日早晚各一次,30天为一个疗程。
4、治疗结果:临床观察结果显示,其中85例免疫力低下者服用本发明药物1个疗程后,体质明显增强,精力充沛,为显效;12例免疫力低下者服用本发明药物1个疗程后,体质有所增强,四肢较有力,为有效;3例免疫力低下者服用本发明药物1个疗程后,症状基本无改善,为无效。总有效率为97%。
Claims (10)
1.一种具有增强免疫力功能的组合物,其特征在于,它是由下列重量份的组分制成的:西洋参1-25份、枸杞子1-20份、刺五加1-15份、茯苓1-20份、炙黄芪1-20份。
2.根据权利要求1所述的组合物,其特征在于,它是由下列重量份的组分制成的:西洋参5-15份、枸杞子3-10份、刺五加3-8份、茯苓3-10份、炙黄芪3-10份。
3.根据权利要求1或2所述的组合物的制备方法,其特征在于,它是这样制备的:
将所述配比的西洋参、枸杞子、刺五加、茯苓、炙黄芪,加乙醇进行提取,提取液合并,过滤,滤液浓缩至稠膏,减压干燥,粉碎成细粉,即得本发明药物的活性成分。
4.根据权利要求3所述的组合物的制备方法,其特征在于,它是这样制备的:
将所述重量配比的西洋参、枸杞子、刺五加、茯苓、炙黄芪,加6-12倍量50-95%乙醇提取1-4次,每次1-3小时,提取液合并,过滤,减压回收乙醇至稠膏,减压干燥,粉碎成细粉,即得本发明药物的活性成分。
5.根据权利要求3或4所述的组合物的制备方法,其特征在于,制得的药物活性组分加入或不加辅料按常规工艺制成药剂学上可接受的制剂。
6.根据权利要求5所述的组合物的制备方法,其特征在于,所述的制剂是口服制剂。
7.根据权利要求6所述的组合物的制剂,其特征在于,所述的口服制剂是指片剂、颗粒剂、胶囊剂、丸剂、散剂、口服液体制剂。
8.根据权利要求7所述的制剂,其特征在于,所述的制剂为颗粒剂。
9.根据权利要求8所述的颗粒剂,其特征在于,它是这样制备的:
将所述重量配比的西洋参、枸杞子、刺五加、茯苓、炙黄芪,加8倍量70%乙醇提取3次,每次1.5小时,提取液合并,过滤,减压回收乙醇至稠膏,减压干燥,粉碎成细粉,加入适量辅料,混匀,以85%乙醇制粒,干燥,整粒,即得。
10.根据权利要求1或2所述的组合物用于在制备增强免疫力的保健食品中的应用。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2012100914136A CN103356807A (zh) | 2012-03-30 | 2012-03-30 | 一种具有增强免疫力功能的组合物及其制备方法 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2012100914136A CN103356807A (zh) | 2012-03-30 | 2012-03-30 | 一种具有增强免疫力功能的组合物及其制备方法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN103356807A true CN103356807A (zh) | 2013-10-23 |
Family
ID=49359609
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2012100914136A Pending CN103356807A (zh) | 2012-03-30 | 2012-03-30 | 一种具有增强免疫力功能的组合物及其制备方法 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103356807A (zh) |
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103609790A (zh) * | 2013-10-31 | 2014-03-05 | 安徽博格生物科技有限公司 | 一种增强免疫、预防疾病的泡袋剂 |
| CN103609788A (zh) * | 2013-10-31 | 2014-03-05 | 安徽博格生物科技有限公司 | 一种滋阴补肾、壮阳的泡袋剂 |
| CN103798473A (zh) * | 2014-01-16 | 2014-05-21 | 戴明传 | 延年益寿养生保健茶 |
| CN104547544A (zh) * | 2014-12-26 | 2015-04-29 | 山东明仁福瑞达制药股份有限公司 | 一种提高免疫力消除慢性疲劳的保健食品组合物 |
| CN104621563A (zh) * | 2015-02-06 | 2015-05-20 | 甘肃宏安生乐生物科技有限公司 | 奉康颗粒 |
| CN105616840A (zh) * | 2016-02-22 | 2016-06-01 | 广西梧州制药(集团)股份有限公司 | 一种增加nk细胞活性的中药组合物及其制备方法 |
| CN108497496A (zh) * | 2018-04-19 | 2018-09-07 | 牡丹江师范学院 | 一种功能性运动营养品及其制备方法 |
| CN112089770A (zh) * | 2020-10-02 | 2020-12-18 | 辽宁泰阳医药科技开发有限公司 | 一种可提高免疫力的组合物及其制备方法 |
-
2012
- 2012-03-30 CN CN2012100914136A patent/CN103356807A/zh active Pending
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103609790A (zh) * | 2013-10-31 | 2014-03-05 | 安徽博格生物科技有限公司 | 一种增强免疫、预防疾病的泡袋剂 |
| CN103609788A (zh) * | 2013-10-31 | 2014-03-05 | 安徽博格生物科技有限公司 | 一种滋阴补肾、壮阳的泡袋剂 |
| CN103609790B (zh) * | 2013-10-31 | 2015-04-15 | 安徽博格生物科技有限公司 | 一种增强免疫、预防疾病的泡袋剂 |
| CN103798473A (zh) * | 2014-01-16 | 2014-05-21 | 戴明传 | 延年益寿养生保健茶 |
| CN104547544A (zh) * | 2014-12-26 | 2015-04-29 | 山东明仁福瑞达制药股份有限公司 | 一种提高免疫力消除慢性疲劳的保健食品组合物 |
| CN104621563A (zh) * | 2015-02-06 | 2015-05-20 | 甘肃宏安生乐生物科技有限公司 | 奉康颗粒 |
| CN105616840A (zh) * | 2016-02-22 | 2016-06-01 | 广西梧州制药(集团)股份有限公司 | 一种增加nk细胞活性的中药组合物及其制备方法 |
| CN108497496A (zh) * | 2018-04-19 | 2018-09-07 | 牡丹江师范学院 | 一种功能性运动营养品及其制备方法 |
| CN112089770A (zh) * | 2020-10-02 | 2020-12-18 | 辽宁泰阳医药科技开发有限公司 | 一种可提高免疫力的组合物及其制备方法 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN109674958B (zh) | 一种具有降尿酸功效的中药组合物及其制备方法和应用 | |
| CN103356807A (zh) | 一种具有增强免疫力功能的组合物及其制备方法 | |
| CN103463458B (zh) | 铁皮石斛复配咀嚼片及其制备方法 | |
| CN103446450B (zh) | 一种具有缓解体力疲劳功能的组合物及其制备方法 | |
| CN104740412B (zh) | 一种解酒剂组合物及其制备方法 | |
| CN101822746A (zh) | 一种具有增强免疫力功能的中药组合物及其制备方法 | |
| CN101612315A (zh) | 一种用于调整人体机能的中药复方制剂 | |
| CN103355655A (zh) | 一种具有改善营养性贫血功能的组合物及其制备方法 | |
| CN106420886A (zh) | 一种具有缓解体力疲劳、增强免疫力功能的组合物及其制备方法 | |
| CN1408397A (zh) | 含褪黑素和益智中药的组合物 | |
| CN106031418A (zh) | 一种具有缓解体力疲劳功能的组合物及其制备方法 | |
| CN107006856A (zh) | 一种增强耐力、提高抗缺氧耐受力营养剂及其制备方法 | |
| CN101856405B (zh) | 一种治疗2型糖尿病的药物组合物及其制备方法 | |
| CN102416101B (zh) | 治疗心力衰竭的中药组合物及其制备方法 | |
| CN103272125B (zh) | 含有霍山石斛的具有降糖作用的中药组合物及其制备方法 | |
| CN101167846A (zh) | 一种具有降糖作用的胶囊及其制备方法 | |
| CN103156956B (zh) | 一种补血口服液及制备方法 | |
| CN105560386A (zh) | 仙人掌片剂及其制备方法 | |
| KR101910013B1 (ko) | 한약재 추출물(socg)을 함유하는 통증의 개선, 예방 또는 치료용 조성물 | |
| CN106177166A (zh) | 一种具有缓解体力疲劳功能的组合物及其制备方法 | |
| CN105168846A (zh) | 一种具有生理功能的口服组合物 | |
| CN104189472A (zh) | 一种治疗原发性低血压病的中药组合物 | |
| CN103610795A (zh) | 一种杜仲降压口服制剂的制备方法 | |
| CN103800789A (zh) | 一种健脾补肾的中药组合物及其制备方法 | |
| CN101342208B (zh) | 一种治疗冠心病、心绞痛、心律失常的中药组合物及其制备方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20131023 |